Specific competitive antagonist at both α- and β-adrenergic receptor sites. Prepn: L. H. Lunts, D. T. Collin, DE 2032642; eidem, US 4012444 (1971, 1977 both to Allen & Hanburys). Synthesis of labetalol and enantiomers: J. E. Clifton et al., J. Med. Chem. 25, 670 (1982); and comparison of cardiovascular properties: E. H. Gold et al., ibid. 1363. Abs config of dilevalol: P. Murray-Rust et al., Acta Crystallogr. C40, 825 (1984). Adrenoceptor blocking properties: E. J. Sybertz et al., J. Pharmacol. Exp. Ther. 218, 435 (1981). HPLC determn in serum or plasma: T. F. Woodman, B. Johnson, Ther. Drug Monit. 3, 371 (1981). Metabolism in animals and man: R. Hopkins et al., Biochem. Soc. Trans. 4, 726 (1976). Toxicity: K. Shimpo et al., Hokkaido Igaku Zasshi 53, 15 (l978), C.A. 90, 66465v (1974). Review of pharmacology: R. Donnelly, G. J. A. Macphee, Clin. Pharmacokinet. 21, 95-109 (1991); of therapeutic applications in hypertension and ischemic heart disease: K. L. Goa et al., Drugs 37, 583-627 (1989).
Antihypertensive.
α-Adrenergic Blocker; β-Adrenergic Blocker; Antihypertensive; Arylethanolamine Derivatives